biotech · Parkinson Disease · Amyotrophic Lateral Sclerosis · DNLI
Denali Therapeutics
Denali Therapeutics clinical programs — 13 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 161 Oyster Point Blvd, South San Francisco, California 94080, US
- Founded
- 2015
- Employees
- 567
- Programs
- 23
- Drugs
- 10
- Patents
- 42
Denali Therapeutics projects
13 ClinicalTrials.gov programs sponsored by Denali Therapeutics.
Denali Therapeutics has 13 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
BIIB122 (DNL151)
Denali Therapeutics
Healthy Volunteers
1 trial -
DNL151
Denali Therapeutics
Healthy Volunteers
1 trial -
DNL201
Denali Therapeutics
Healthy Volunteers
1 trial -
DNL201
Denali Therapeutics
Parkinson Disease
1 trial -
DNL343
Denali Therapeutics
Healthy Volunteers
2 trials -
DNL628
Denali Therapeutics
Alzheimer Disease, Early Onset
1 trial -
DNL747
Denali Therapeutics
Amyotrophic Lateral Sclerosis
1 trial -
DNL747
Denali Therapeutics
Alzheimer Disease
1 trial -
DNL919
Denali Therapeutics
Healthy Participant
1 trial -
DNL952
Denali Therapeutics
Late-onset Pompe Disease
1 trial -
DNLI-K-0001
Denali Therapeutics
Early Alzheimer's Disease
1 trial -
[14C] BIIB122 ([14C] DNL151)
Denali Therapeutics
Healthy Volunteers
1 trial -
[14C]-DNL343
Denali Therapeutics
Healthy Volunteers
1 trial
Frequently asked questions
How many clinical projects does Denali Therapeutics have?
13 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.